This study investigated the stability of MGMT promoter methylation in recurrent glioma patients to inform treatment decisions. Researchers analyzed paired tumor samples from 426 patients, revealing that MGMT methylation status remained unchanged in 84% of cases. The 16% of observed changes primarily occurred in tumors with initial methylation levels near classification thresholds. These findings suggest that reassessing MGMT status at recurrence, with quantitative reporting, could improve therapeutic decision-making, particularly for temozolomide rechallenge.
This single-center retrospective study investigated the prognostic impact of MGMT promoter methylation and TERT promoter mutations in 54 patients with WHO grade 4 glioblastoma. The findings indicate that MGMT methylation is independently associated with improved overall survival, whereas TERT mutations predict worse survival. Adjuvant chemoradiotherapy was also confirmed to improve outcomes. A combined stratification using both biomarkers allows for the identification of four distinct prognostic subgroups, with MGMT-methylated/TERT-wild-type patients exhibiting the longest survival.
This study established 18 patient-derived glioblastoma organoid (GBO) lines that faithfully preserve the histopathological and genomic features of parental tumors. Glioblastoma organoid-based drug sensitivity testing (GBO-DST) demonstrated a strong correlation with progression-free survival and proved superior to MGMT methylation status in predicting temozolomide response. Transcriptomic analysis elucidated mechanisms of temozolomide resistance, including mismatch repair deficiency and elevated MGMT expression. Furthermore, FDA-approved drug screening using GBO-DST identified regorafenib and lazertinib as effective therapeutic alternatives, with lazertinib showing superior efficacy in a GBO transplantation mouse model. These findings highlight the significant potential of GBO-DST as a robust platform for precision oncology in glioblastoma.